Express News | AIM ImmunoTech Inc - Files Prospectus Relates to Offer & Resale of up to 9.97 Mln Shares of Common Stock by Selling Stockholder
Moomoo 24/7Apr 19 17:04 ET
Analytical Instrument Management Acquires PSI Laboratories
LITTLETON, Colo., April 18, 2024 /PRNewswire/ -- Analytical Instrument Management (AIM) proudly announces its acquisition of PSI Laboratories, a well-established full-service analytical laboratory ba
PR NewswireApr 18 08:34 ET
Express News | AIM ImmunoTech Announces Charles Lapp, Md, as a Consulting Medical Officer for Its Me/Cfs and Long Covid Programs
Moomoo 24/7Apr 15 08:55 ET
Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the
Dow JonesApr 11 11:00 ET
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 11, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO
AIM ImmunoTechApr 11 00:00 ET
Express News | AIM ImmunoTech Announces Top-Line, Protocol-Planned Interim Report Data From Study Of Ampligen Combined With Pembrolizumab For Recurrent Ovarian Cancer
Moomoo 24/7Apr 10 08:22 ET
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data From the Study of Ampligen Combined With Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab)
AIM ImmunoTechApr 10 00:00 ET
AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript
Yahoo FinanceApr 3 09:01 ET
AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.15) by 73.33 percent. This is a 188.89 percent decrease over losses of $(0.0
BenzingaApr 2 22:58 ET
Earnings Call Summary | AIM ImmunoTech(AIM.US) Q4 2023 Earnings Conference
The following is a summary of the AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript:Financial Performance:AIM ImmunoTech reports having sufficient funds to continue operational and clinical a
moomoo AIApr 2 11:38 ET · Conference Call
Express News | AIM ImmunoTech Reported Cash, Cash Equivalents And Marketable Investments Of $13.1M, As Of December 31, 2023
Moomoo 24/7Apr 2 07:34 ET
AIM ImmunoTech GAAP EPS of -$0.60, Revenue of $0.2M
Seeking AlphaApr 2 07:34 ET
Earnings Scheduled For April 2, 2024
Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter. • Allego (NYSE:ALLG) is projected to report quarterly loss at $0.04 per share on reve
BenzingaApr 2 06:25 ET
Navigating the Future: Aim Immunotech's Challenge Against Rapid Tech Evolution in Pharma
TipRanksApr 2 02:00 ET
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Year marked by growing body of promising data demonstrating Ampligen's potential to address multiple high-value indicationsCompany to host conference call and webcast today, April 2nd at 8:30 AM ET OC
AIM ImmunoTechApr 2 00:00 ET
AIM ImmunoTech FY 2023 Earnings Preview
Seeking AlphaApr 1 13:48 ET
Notable Earnings Before Tuesday's Open
Seeking AlphaApr 1 09:48 ET
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ETOCALA, Fla., March 28, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels,
AIM ImmunoTechMar 28 00:00 ET
Earnings Scheduled For March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report
BenzingaMar 26 04:47 ET
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
OCALA, Fla., March 26, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q4/F
AIM ImmunoTechMar 26 00:00 ET
No Data
No Data